ARVN003

ARVN003, known as MicroLine in US, is a pharmacologic treatment for presbyopia developed by Eyenovia, Inc. (NASDAQ: EYEN). Current treatment options for presbyopia are typically device-based, such as reading glasses and contact lenses. Pilocarpine ophthalmic solution is known to constrict the pupil and improve near-distance vision by creating an extended depth of focus through its small aperture effect. 

We believe that administration of pilocarpine using the Eyenovia's high precision microdosing technology (MAP™) could provide a meaningful improvement in near vision while enhancing tolerability and usability.